Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
Holding TXG?
Track your performance easily
TXG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.28 - $57.90
Previous Close$22.37
Volume1.06M
Average Volume (3M)1.84M
Market Cap
$2.59B
Enterprise Value$2.40B
Total Cash (Recent Filing)$380.09M
Total Debt (Recent Filing)$89.48M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Oct 30, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding120,491,417
10 Day Avg. Volume1,286,591
30 Day Avg. Volume1,837,297
Standard Deviation0.17
R-Squared0.33
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.72
Price to Sales (P/S)4.27
Price to Cash Flow (P/CF)89.90
P/FCF Ratio186.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.81
Enterprise Value/Gross Profit5.88
Enterprise Value/Ebitda-12.81
Forecast
1Y Price Target
$26.55Price Target Upside23.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
10x Genomics News
PremiumCompany Announcements
10x Genomics Appoints Adam Taich as New CFO
Bulls Say, Bears Say
Bulls Say
Market PositionTXG's Xenium has emerged as the #1 platform for Spatial.
Product LaunchThe launch of a lower-cost instrument for single-cell analysis may help drive increased shipments amid the current macro pressures on capital equipment spending.
Revenue GrowthService revenue increased significantly by 74% year over year.
Bears Say
CompetitionIllumina acquired private single-cell company Fluent BioSciences, which appeared to pressure TXG shares due to potential competitive headwinds.
Financial PerformanceThe capital equipment purchasing environment has been challenged for multiple years, negatively impacting the financial performance of many life science instrumentation companies.
Revenue GuidanceThe company lowered its 2024 revenue guidance by 4% at the midpoint.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $15.28 and its highest was $57.90 in the past 12 months.
What is 10x Genomics Inc’s market cap?
Currently, no data Available
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Oct 30, 2024 which is in 41 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Aug 08, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.479 by $0.159.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -$0.33.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 106,434,586 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.479. Following the earnings report the stock price went up 4.501%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Among the largest hedge funds holding 10x Genomics Inc’s share is ARK Investment Management LLC. It holds 10x Genomics Inc’s shares valued at 181M.
---
10x Genomics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.55 (23.37% Upside)
$26.55 (23.37% Upside)
Blogger Sentiment
Bullish
TXG Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $316.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.15%
12-Months-Change
Fundamentals
Return on Equity
-31.61%
Trailing 12-Months
Asset Growth
-6.06%
Trailing 12-Months
Company Description
10x Genomics Inc
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.
---
TXG Earnings Call
Q2 2024
0:00 / 0:00
---
TXG Revenue Breakdown
77.51% Consumables
19.96% Instruments
2.54% Services
---
TXG Stock 12 Month Forecast
Average Price Target
$26.55
▲(23.37% Upside)
Best Analysts Covering TXG
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
-4.84%
assigned a buy rating last month
Copying Tejas Savant's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of -4.84% per trade.
---